From the Department of Nephrology, General Hospital of Nikea, Athens, Greece.
From the School of Medicine, Institute of Life Course and Medical Sciences, Faculty of Health and Science, University of Liverpool, Liverpool, United Kingdom.
Exp Clin Transplant. 2022 Jan;20(1):1-11. doi: 10.6002/ect.2021.0133. Epub 2021 Nov 11.
Kidney allograft failure is a significant complication in kidney transplant recipients, and the surgical decision to perform allograft nephrectomy poses a strong dilemma because it is associated with significant morbidity and mortality. There is a debate over the effect of allograft nephrectomy on the development of allosensitization and the impact on potential retransplantation. Moreover, the use of immunosuppression may contribute to antibody allosensitization as allograft nephrectomy and immunosuppression act jointly and interdependently toward antibody formation. Because more and more patients with kidney allograft failure are entering wait lists for repeat transplant procedures, a review of available evidence on the field is required. Here, we performed a literature search using multiple medical databases to identify relevant studies that assessed the effects of allograft nephrectomy on important retransplant endpoints such as allograft and patient survival; furthermore, secondary outcomes such as alloantibody sensitization were also evaluated. A total of 15 studies were identified; all were retrospective, single-center studies. The rate of allograft nephrectomy in patients with retransplant varied widely (from 20% to 80%). The average allograft nephrectomy rate in included studies was 43% (allograft nephrectomy number/number of repeat transplantations: 2351/5431). Most studies did not observe an allograft survival benefit after retransplant for patients with allograft nephrectomy with the exception of 4 studies that found worse allograft survival after allograft nephrectomy. Interestingly, 1 study found that, in the patient subgroup with early kidney allograft failure (<12 months posttransplant), allograft nephrectomy may be associated with better allograft survival. Available data suggested that allograft nephrectomy may be associated with a higher risk of increasing anti-HLA antibody levels. The quality of the included studies suffered from nonrandomized design, potential confounding, and small sample size. To conclude, further randomized controlled trials are required to delineate the role of allograft nephrectomy on retransplant outcomes.
肾移植失败是肾移植受者的一个严重并发症,而进行同种异体肾切除术的手术决策带来了强烈的困境,因为它与显著的发病率和死亡率相关。同种异体肾切除术对同种异体致敏的发展和对潜在再移植的影响存在争议。此外,免疫抑制的使用可能导致抗体同种异体致敏,因为同种异体肾切除术和免疫抑制共同作用并相互依存,以形成抗体。由于越来越多的肾移植失败患者进入重复移植手术的等候名单,因此需要对该领域的现有证据进行审查。在这里,我们使用多个医学数据库进行了文献检索,以确定评估同种异体肾切除术对重要再移植终点(如移植物和患者存活率)影响的相关研究;此外,还评估了次要结局,如同种异体抗体致敏。共确定了 15 项研究;所有研究均为回顾性、单中心研究。再移植患者的同种异体肾切除术率差异很大(从 20%到 80%)。纳入研究的平均同种异体肾切除术率为 43%(同种异体肾切除术数量/重复移植数量:2351/5431)。除了 4 项研究发现同种异体肾切除术后移植物存活率较差外,大多数研究在同种异体肾切除术后再移植患者中未观察到移植物存活获益。有趣的是,1 项研究发现,在早期肾移植失败(<12 个月移植后)的患者亚组中,同种异体肾切除术可能与更好的移植物存活率相关。现有数据表明,同种异体肾切除术可能与增加抗 HLA 抗体水平的风险较高相关。纳入研究的质量受到非随机设计、潜在混杂因素和样本量小的影响。总之,需要进一步的随机对照试验来阐明同种异体肾切除术对再移植结局的作用。